Medifast Management

Management Kriterienprüfungen 3/4

Medifast's CEO ist Dan Chard , ernannt in Oct 2016, hat eine Amtszeit von 7.67 Jahren. Die jährliche Gesamtvergütung beträgt $7.04M , bestehend aus 14.2% Gehalt und 85.8% Boni, einschließlich Aktien und Optionen des Unternehmens. besitzt direkt 1.46% der Aktien des Unternehmens, im Wert von €2.90M . Die durchschnittliche Betriebszugehörigkeit des Managementteams und des Verwaltungsrats beträgt 4.3 Jahre bzw. 7.7 Jahre.

Wichtige Informationen

Dan Chard

Geschäftsführender

US$7.0m

Gesamtvergütung

Prozentsatz des Geschäftsführergehalts	14.2%
Amtszeit als Geschäftsführer	7.7yrs
Eigentum des Geschäftsführers	1.5%
Durchschnittliche Amtszeit des Managements	4.3yrs
Durchschnittliche Amtszeit der Vorstandsmitglieder	7.7yrs

Jüngste Management Updates

Recent updates

Analyse der Geschäftsführervergütung

Wie hat sich die Vergütung von Dan Chard im Vergleich zu den Einnahmen von Medifast verändert?
Datum	Gesamtvergütung	Gehalt	Unternehmensgewinne
Mar 31 2024	n/a	n/a	US$68m
Dec 31 2023	US$7m	US$1m	US$99m
Sep 30 2023	n/a	n/a	US$120m
Jun 30 2023	n/a	n/a	US$133m
Mar 31 2023	n/a	n/a	US$142m
Dec 31 2022	US$6m	US$981k	US$144m
Sep 30 2022	n/a	n/a	US$151m
Jun 30 2022	n/a	n/a	US$157m
Mar 31 2022	n/a	n/a	US$165m
Dec 31 2021	US$7m	US$914k	US$164m
Sep 30 2021	n/a	n/a	US$158m
Jun 30 2021	n/a	n/a	US$150m
Mar 31 2021	n/a	n/a	US$125m
Dec 31 2020	US$6m	US$909k	US$103m
Sep 30 2020	n/a	n/a	US$95m
Jun 30 2020	n/a	n/a	US$76m
Mar 31 2020	n/a	n/a	US$76m
Dec 31 2019	US$5m	US$843k	US$78m
Sep 30 2019	n/a	n/a	US$74m
Jun 30 2019	n/a	n/a	US$72m
Mar 31 2019	n/a	n/a	US$64m
Dec 31 2018	US$2m	US$675k	US$56m
Sep 30 2018	n/a	n/a	US$47m
Jun 30 2018	n/a	n/a	US$40m
Mar 31 2018	n/a	n/a	US$34m
Dec 31 2017	US$2m	US$650k	US$28m

Vergütung im Vergleich zum Markt: DanDie Gesamtvergütung ($USD7.04M) liegt über dem Durchschnitt von Unternehmen ähnlicher Größe auf dem Markt German ($USD759.28K).

Entschädigung vs. Einkommen: DanDie Vergütung des Vorstandsvorsitzenden entsprach im vergangenen Jahr der Unternehmensleistung.

Geschäftsführer

Dan Chard (59 yo)

7.7yrs

Amtszeit

US$7,039,062

Vergütung

Mr. Daniel R. Chard, also known as Dan, has been Chief Executive Officer of Medifast, Inc. since October 3, 2016 and Director since October 3, 2016 and also serves as its Executive Chairman since December...

Führungsteam

Name	Position	Amtszeit	Vergütung	Eigentümerschaft
Daniel Chard	Executive Chairman & CEO	7.7yrs	US$7.04m	1.46% $ 2.8m
James Maloney	Chief Financial Officer	3.9yrs	US$2.01m	0.091% $ 178.4k
Anthony Tyree	Chief Business Operations Officer	2.4yrs	US$1.61m	0.12% $ 228.1k
Jason Groves	Executive VP	12.6yrs	US$1.63m	0.12% $ 227.1k
Nicholas Johnson	Chief Field Operations Officer	5.3yrs	US$1.70m	0.095% $ 185.7k
Jonathan MacKenzie	VP of Finance & Chief Accounting Officer	2.8yrs	keine Daten	0.0050% $ 9.7k
Steven Zenker	Vice President of Investor Relations	1.3yrs	keine Daten	keine Daten
Claudia Greninger	Chief Human Resources Officer	4.7yrs	keine Daten	keine Daten

4.3yrs

Durchschnittliche Betriebszugehörigkeit

53yo

Durchschnittliches Alter

Erfahrenes Management: MDFDas Führungsteam des Unternehmens gilt als erfahren (4.3 Jahre durchschnittliche Betriebszugehörigkeit).

Vorstandsmitglieder

Name	Position	Amtszeit	Vergütung	Eigentümerschaft
Daniel Chard	Executive Chairman & CEO	7.7yrs	US$7.04m	1.46% $ 2.8m
Jeffrey Brown	Lead Independent Director	9yrs	US$263.42k	0.054% $ 105.8k
George Bray	Member of Scientific Advisory Board	no data	keine Daten	keine Daten
Michael Hoer	Independent Director	6yrs	US$249.72k	0.017% $ 32.6k
Andrea Thomas	Independent Director	5yrs	US$249.72k	0.058% $ 114.4k
John Foreyt	Member of Scientific Advisory Board	no data	keine Daten	keine Daten
Ming Xian	Independent Director	6yrs	US$219.61k	keine Daten
Lawrence Cheskin	Chairman of Scientific Advisory Board	15.6yrs	keine Daten	keine Daten
Sylvia Rowe	Member of Scientific Advisory Board	no data	keine Daten	keine Daten
Scott Schlackman	Independent Director	9yrs	US$252.44k	0.099% $ 192.7k
John Hayes	Member of Scientific Advisory Board	no data	keine Daten	keine Daten
Mark Messina	Member of Scientific Advisory Board	no data	keine Daten	keine Daten

7.7yrs

Durchschnittliche Betriebszugehörigkeit

62.5yo

Durchschnittliches Alter

Erfahrener Vorstand: MDFDie Vorstandsmitglieder gelten als erfahren (7.6 Jahre durchschnittliche Amtszeit).

Medifast Management

Management Kriterienprüfungen 3/4

Wichtige Informationen

Jüngste Management Updates

Independent Director recently sold €99k worth of stock

Medifast, Inc., Annual General Meeting, Jun 14, 2023

Insufficient new directors

Lead Independent Director recently bought €487k worth of stock

Medifast Announces New Scientific Advisory Board Appointments

Executive Chairman & CEO recently bought €75k worth of stock

Recent updates

Now 24% overvalued

Now 22% overvalued

Investor sentiment improves as stock rises 17%

Now 20% overvalued

Investor sentiment deteriorates as stock falls 26%

New major risk - Revenue and earnings growth

First quarter 2024 earnings released: EPS: US$0.76 (vs US$3.68 in 1Q 2023)

Medifast, Inc. Provides Earnings Guidance for the Second Quarter of 2024

Medifast, Inc. to Report Q1, 2024 Results on Apr 29, 2024

Investor sentiment deteriorates as stock falls 16%

Independent Director recently sold €99k worth of stock

Investor sentiment deteriorates as stock falls 16%

New major risk - Revenue and earnings growth

New minor risk - Share price stability

Full year 2023 earnings released: EPS: US$9.13 (vs US$12.82 in FY 2022)

Medifast Provides Earnings Guidance for the First Quarter of 2024

Medifast, Inc. to Report Q4, 2023 Results on Feb 20, 2024

Medifast, Inc. Provides Earnings Guidance for the Full Year 2023

Third quarter 2023 earnings released: EPS: US$2.12 (vs US$3.30 in 3Q 2022)

New minor risk - Insider selling

Medifast, Inc. to Report Q3, 2023 Results on Nov 06, 2023

Medifast, Inc. Announces Optavia Active Now Available

Medifast, Inc. Declares Quarterly Cash Dividend, Payable on November 7, 2023

Medifast, Inc. Provides Earnings Guidance for the Third Quarter 2023

Second quarter 2023 earnings released: EPS: US$2.78 (vs US$3.45 in 2Q 2022)

Medifast Unveils New Product Line, Optavia Active

Medifast, Inc. to Report Q2, 2023 Results on Aug 07, 2023

Now 20% undervalued after recent price drop

Medifast, Inc. Declares Quarterly Cash Dividend, Payable on August 8, 2023

Medifast, Inc., Annual General Meeting, Jun 14, 2023

First quarter 2023 earnings released: EPS: US$3.68 (vs US$3.62 in 1Q 2022)

Full year 2022 earnings released: EPS: US$12.82 (vs US$14.01 in FY 2021)

Medifast, Inc. to Report Q4, 2022 Results on Feb 21, 2023

Upcoming dividend of US$1.64 per share

Medifast, Inc. Announces Quarterly Dividend, Payable on February 7, 2023

Insufficient new directors

Now 23% undervalued after recent price drop

Medifast, Inc. Revises Earnings Guidance for the Year 2022

Medifast, Inc. to Report Q3, 2022 Results on Nov 03, 2022

Upcoming dividend of US$1.64 per share

Medifast Announces Quarterly Dividend, Payable on November 8, 2022

Lead Independent Director recently bought €487k worth of stock

Investor sentiment deteriorated over the past week

Second quarter 2022 earnings released: EPS: US$3.45 (vs US$4.00 in 2Q 2021)

Medifast, Inc. Revises Earnings Guidance for the Full-Year of 2022

Medifast Announces New Scientific Advisory Board Appointments

Medifast, Inc. to Report Q2, 2022 Results on Aug 03, 2022

Medifast, Inc.(NYSE:MED) dropped from Russell 2000 Dynamic Index

Upcoming dividend of US$1.64 per share

Medifast, Inc. Announces Quarterly Dividend, Payable on August 8, 2022

Executive Chairman & CEO recently bought €75k worth of stock

First quarter 2022 earnings released: EPS: US$3.62 (vs US$3.49 in 1Q 2021)

Medifast, Inc. Revises Earnings Guidance for the Full-Year of 2022

Insufficient new directors

Medifast, Inc., Annual General Meeting, Jun 15, 2022

Medifast, Inc. to Report Q1, 2022 Results on May 02, 2022

Now 21% undervalued after recent price drop

Insider recently sold €182k worth of stock

Now 20% undervalued after recent price drop

Medifast, Inc. Provides Earnings Guidance for the Full-Year 2022

Full year 2021 earnings: Revenues and EPS in line with analyst expectations

Medifast, Inc. to Report Q4, 2021 Results on Feb 23, 2022

Upcoming dividend of US$1.42 per share

Insufficient new directors

Third quarter 2021 earnings released: EPS US$3.59 (vs US$2.93 in 3Q 2020)

Independent Director recently sold €128k worth of stock

VP of Finance & Chief Accounting Officer Stephen Johnson has left the company

Medifast, Inc. Provides Earnings Guidance for 2021

Second quarter 2021 earnings released: EPS US$4.00 (vs US$1.86 in 2Q 2020)